Literature DB >> 8143061

Effect of oral prednisone on airway inflammatory mediators in atopic asthma.

R Dworski1, G A Fitzgerald, J A Oates, J R Sheller.   

Abstract

The mechanism of steroid action in asthma is unknown. Because steroids have effects in vitro on eicosanoid synthesis, we determined the effect of oral prednisone for 6 to 9 days on eicosanoid levels in bronchoalveolar lavage (BAL) fluid of 14 atopic asthmatic volunteers at baseline and after allergen instillation. We also determined the effect of prednisone on the ex vivo release of eicosanoids from macrophage-rich BAL-fluid cells. Prednisone reduced symptoms and inhaler use but had no significant effect on BAL-fluid eicosanoid levels. At baseline, prostaglandin D2 (PGD2) levels were 101 +/- 37 pg/ml in BAL fluid (mean +/- SEM), versus 66 +/- 18 pg/ml after prednisone; likewise, 5-hydroxy eicosatetraenoic acid (5-HETE) levels were 59 +/- 15 versus 78 +/- 21; leukotriene E4 (LTE4) levels were 35 +/- 13 versus 51 +/- 21, and 15-hydroxy eicosatetraenoic acid (15-HETE) levels were 29 +/- 8 versus 19 +/- 7. Allergen-stimulated levels of PGD2 were 1274 +/- 565 versus 1468 +/- 679 after prednisone; likewise, allergen-stimulated 5-HETE levels were 95 +/- 21 versus 82 +/- 21; those of LTE4 were 54 +/- 20 versus 91 +/- 51; and those of 15-HETE were 63 +/- 19 versus 60 +/- 25. Prednisone reduced the synthesis of eicosanoids in macrophage-rich BAL-fluid cells in vitro. LTB4 levels fell significantly from 35 +/- 6.4 ng/10(6) BAL-fluid cells to 17 +/- 5.4 after prednisone; likewise, levels of thromboxane B2 (TXB2) fell from 35.7 +/- 7.5 to 20.7 +/- 6.6. Part of the action of steroids may involve alteration in macrophage eicosanoid synthesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8143061     DOI: 10.1164/ajrccm.149.4.8143061

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  39 in total

Review 1.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Leukotriene receptor antagonist therapy.

Authors:  O J Dempsey
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

Review 3.  Aspirin-induced asthma.

Authors:  L T Vaszar; D D Stevenson
Journal:  Clin Rev Allergy Immunol       Date:  2001-08       Impact factor: 8.667

Review 4.  New treatments for asthma: the role of leukotriene modifier agents.

Authors:  D J Valacer
Journal:  J Natl Med Assoc       Date:  1999-08       Impact factor: 1.798

Review 5.  A centennial history of research on asthma pathogenesis.

Authors:  Michael J Walter; Michael J Holtzman
Journal:  Am J Respir Cell Mol Biol       Date:  2005-06       Impact factor: 6.914

6.  Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids.

Authors:  T F Reiss; C A Sorkness; W Stricker; A Botto; W W Busse; S Kundu; J Zhang
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

7.  Montelukast in asthma: a review of its efficacy and place in therapy.

Authors:  Pierluigi Paggiaro; Elena Bacci
Journal:  Ther Adv Chronic Dis       Date:  2011-01       Impact factor: 5.091

8.  Montelukast - evaluation in 6 to 14 years old children with persistent asthma - pediatric montelukast study group.

Authors:  Sham Kukreja; S Sanjay; Gautam Ghosh; K K Aggarwal; Ashok Moharana
Journal:  Indian J Pediatr       Date:  2004-09       Impact factor: 1.967

9.  Corticosteroid suppression of lipoxin A4 and leukotriene B4 from alveolar macrophages in severe asthma.

Authors:  Pankaj K Bhavsar; Bruce D Levy; Mark J Hew; Michael A Pfeffer; Shamsah Kazani; Elliot Israel; Kian Fan Chung
Journal:  Respir Res       Date:  2010-06-07

10.  Blocking leukotrienes optimize asthma control: the BLOC survey.

Authors:  Majdy M Idrees; Mohamed S Al Moamary
Journal:  Ann Thorac Med       Date:  2007-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.